

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-2 (canceled).

Claim 3 (currently amended): A compound of Claim 1 wherein said compound has the (R, R) stereo configuration.

Claims 4 (withdrawn): A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or an animal which comprises administering to said human or animal an effective amount of a compound of Claim 1.

Claim 5 (withdrawn): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Claim 6 (currently amended): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 7 (withdrawn): A pharmaceutical formulation according to Claim 6 which further comprises a bone-antiresorptive agent.

Claim 8 (withdrawn): A method according to Claim 5 which further comprises administering to a patient a bone-antiresorptive agent.

Claim 9 (withdrawn): A method according to Claim 8 wherein said bone-antiresorptive agent is a bisphosphonate.

Claims 10-12 (canceled).


6

Claim ~~13~~<sup>6</sup> (currently amended): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim ~~10~~<sup>17</sup>, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 14 (withdrawn): A pharmaceutical formulation according to Claim 13 which further comprises a bone-antiresorptive agent.


Claim 15 (withdrawn): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 10 or a pharmaceutically acceptable salt or solvate thereof.

Claim ~~16~~ (new): A compound selected from the group consisting of the following structurally depicted compounds:




or a pharmaceutically acceptable salt or solvate thereof.

<sup>2</sup>  
Claim ~~17~~ (new). A compound according to Claim ~~16~~ having the formula




or a pharmaceutically acceptable salt or solvate thereof.

<sup>3</sup>  
Claim ~~18~~ (new). A compound according to Claim ~~16~~ having the formula



or a pharmaceutically acceptable salt or solvate thereof.

4  
Claim ~~19~~<sup>1</sup> (new). A compound according to Claim ~~16~~<sup>1</sup> having the formula



or a pharmaceutically acceptable salt or solvate thereof.

Claim 20 (new). A compound of Claim 17 wherein said compound has the (R, R) stereo configuration.

Claim 21 (new). A compound of Claim 18 wherein said compound has the (R, R) stereo configuration.

Claim 22 (new). A compound of Claim 19 wherein said compound has the (R, R) stereo configuration.

3 7  
Claim ~~22~~<sup>3 7</sup> (new). A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 18<sup>3</sup>, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

8  
Claim ~~24~~<sup>8</sup> (new). A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 19<sup>4</sup>, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Rule 126